NasdaqCM - Nasdaq Real Time Price USD

Alzamend Neuro, Inc. (ALZN)

0.6581
+0.1181
+(21.87%)
At close: May 9 at 4:00:00 PM EDT
0.6190
-0.04
(-5.94%)
After hours: May 9 at 7:42:49 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ALZN

Recent News: ALZN

View More
Alzamend Neuro Announces Reverse Stock Split

Alzamend Neuro Announces Reverse Stock Split
GlobeNewswire 2 days ago
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
GlobeNewswire 3 days ago
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program

EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
Benzinga 3 days ago
Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Alzamend Neuro (ALZN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Zacks last month
Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?

Is Alzamend Neuro, Inc. (ALZN) the Cheapest Stock Insiders Are Buying In March?
Insider Monkey last month
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
GlobeNewswire last month
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
GlobeNewswire last month
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
GlobeNewswire last month
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
GlobeNewswire 2 months ago
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
GlobeNewswire 2 months ago
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025

EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Benzinga 2 months ago
View More

Related Tickers

WINT Windtree Therapeutics, Inc.
0.8522
+0.39%
 
GRI GRI Bio, Inc.
1.4700
-8.12%
 
THAR Tharimmune, Inc.
1.5100
+1.34%
 
LYRA Lyra Therapeutics, Inc.
0.0982
+4.03%
 
GLMD Galmed Pharmaceuticals Ltd.
1.2400
-0.80%
 
PHIO Phio Pharmaceuticals Corp.
1.7600
-2.22%
 
VIVS VivoSim Labs, Inc.
1.9000
-4.04%
 
ZVSA ZyVersa Therapeutics, Inc.
0.5272
-7.70%
 
AEON AEON Biopharma, Inc.
0.4734
+3.36%
 
CGTX Cognition Therapeutics, Inc.
0.3011
-8.76%